R. Scott Struthers

Publications by Year

Research Areas

Hypothalamic control of reproductive hormones, Receptor Mechanisms and Signaling, Chemical Synthesis and Analysis, Estrogen and related hormone effects, Pituitary Gland Disorders and Treatments

Most-Cited Works

• → Differential Desensitization, Receptor Phosphorylation, β-Arrestin Recruitment, and ERK1/2 Activation by the Two Endogenous Ligands for the CC Chemokine Receptor 7(2004)327 cited
• → Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant(1991)306 cited
• → Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix(2008)122 cited
• → Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor(2008)117 cited
• → Distinct Conformations of the Corticotropin Releasing Factor Type 1 Receptor Adopted following Agonist and Antagonist Binding Are Differentially Regulated(2005)60 cited
• → Non-Peptide Gonadotropin-Releasing Hormone Receptor Antagonists(2008)59 cited
• → 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a Potent and Orally Active Antagonist of the Human Gonadotropin-Releasing Hormone Receptor. Design, Synthesis, and in Vitro and in Vivo Characterization(2005)53 cited
• → Molecular Dynamics and Minimum Energy Conformations of GnRH and Analogs: A Methodology for Computer‐aided Drug Designa(1985)50 cited
• → Design of biologically active, conformationally constrained GnRH antagonists(1990)49 cited
• → Activin inhibits binding of transcription factor Pit-1 to the growth hormone promoter.(1992)46 cited